Novo Nordisk A/S (NVO)
| Market Cap | 163.53B |
| Revenue (ttm) | 20.81B |
| Net Income (ttm) | 6.91B |
| Shares Out | 2.36B |
| EPS (ttm) | 2.46 |
| PE Ratio | 28.27 |
| Forward PE | 23.36 |
| Dividend | $1.23 |
| Dividend Yield | 1.76% |
| Trading Day | March 5 |
| Last Price | $69.61 |
| Previous Close | $69.22 |
| Change ($) | 0.39 |
| Change (%) | 0.56% |
| Day's Open | 69.24 |
| Day's Range | 67.92 - 69.78 |
| Day's Volume | 1,322,896 |
| 52-Week Range | 49.24 - 75.86 |
Bagsværd, Denmark, 1 March 2021 – On 3 February 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and ...
Bagsværd, Denmark, 23 February 2021 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 25 March 2021 at 14:00 (CET)
Bagsværd, Denmark, 17 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...
Bagsværd, Denmark, 12 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...
Bagsværd, Denmark, 10 February 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons...
Health care: Novo Nordisk CEO discusses 7% sales growth in 2020 and overall industry
Yahoo Finance's Brian Sozzi, Julie Hyman, and Myles Udland speak with Novo Nordisk CEO Lars Jørgensen about the company's healthcare treatments and outlook. #healthcare Subscribe to Yahoo Fina...
Bagsværd, Denmark, 5 February 2021 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associa...
Novo Nordisk (NVO) beats both earnings and sales estimates for the fourth quarter of 2020.
Shares of Novo Nordisk (NYSE:NVO) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share rose 14.29% year over year to $0.64, which were in line with the es...
Financial report for the period 1 January 2020 to 31 December 2020
Bagsværd, Denmark, 2 February 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...
While stocks keep going up and up, more risks are mounting under the surface. As such, you should be looking at safe stocks to buy now.
Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.
Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing author...
Novo Nordisk is the global leader in obesity and diabetes treatments. There is evidence that the lockdowns increased the number of people suffering from obesity.
Novo Nordisk is a well-managed business with long-term growth opportunities. It is the world market leader in diabetes and obesity care.
Bagsværd, Denmark, 18 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...
Novo Nordisk A/S (NVO) CEO Lars Jørgensen Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)
Bagsværd, Denmark, 11 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...
PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insura...
In view of the overheated markets, it is worthwhile to take a look at the not so well-trodden paths. However, investors are facing a dilemma. There are a lot of great companies, but only a sma...
Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.
Bagsværd, Denmark, 29 December 2020 – Novo Nordisk today announced the submission of a label extension application to the European Medicines Agency (EMA) for the existing marketing authorisati...
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have outperformed the S&P 500 Index over the past 12 months through Dec. 22.
Bagsværd, Denmark, 22 December 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
Novo Nordisk (NVO) files application in Europe for the label expansion of subcutaneous Ozempic (semaglutide) 2.4 mg.
Bagsværd, Denmark 18 December 2020 – Novo Nordisk today announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for subcutaneous semaglu...
Bagsværd, Denmark, 16 December 2020 – Novo Nordisk today announced the decision to enter phase 3 development in Alzheimer's disease with 14 mg oral semaglutide, a once-daily oral formulation o...
ROSELAND, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced the completion of the previously announced transaction whereby Nov...
One metric shows that decades of dominance treating diabetes has created unrivaled profitability.
Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.
Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.
Bagsværd, Denmark, 7 December 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament a...
Bagsværd, Denmark, 7 December 2020 – The Danish Maritime and Commercial High Court has ruled that Novo Nordisk's publication of the press release of 19 September 2019: "Tresiba® showed an ove...
Bagsværd, Denmark, 4 December 2020 – Novo Nordisk today announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for subcutaneous semaglutide 2.4 m...
These 7 cheap stocks span industry and have a great chance to appreciate in price next year. Click here for the metrics and reasoning.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Emispher...
Novo Nordisk A/S (NVO) CEO Lars Jørgensen on ESG Conference Call - Transcript
Let's see if Novo Nordisk A/S (NVO) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Bagsværd, Denmark, 23 November 2020 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...
Novo Nordisk's (NVO) semaglutide 2.0 mg demonstrates superior reduction in HbA1c versus once-weekly semaglutide 1.0 mg in people with type II diabetes.
Gilead (GILD) and Novo Nordisk present favorable outcomes from a mid-stage study in NASH patients.
Danish pharmaceutical giant Novo Nordisk AS (NYSE:NVO) hopes to apply a unique drug delivery technology it acquired to enable people to take more of its drugs by mouth.
Novo Nordisk, trading near record highs, early Friday announced it would buy a maker of proprietary oral drug delivery technology, a longtime partner, for $1.8 billion, and NVO stock rose. The...
Bagsværd , Denmark, 6 November 202 0 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated person...
ROSELAND, N.J., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (“Emisphere” or the “Company”) today announced that it has entered into a definitive agreement with Novo Nordisk ...
About NVO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration a... [Read more...]
| Industry Biotechnology | Founded 1923 |
| CEO Lars Fruergaard Joergensen | Employees 44,723 |
| Stock Exchange NYSE | Ticker Symbol NVO |
Financial Performance
In 2020, NVO's revenue was 126.95 billion, an increase of 4.04% compared to the previous year's 122.02 billion. Earnings were 42.14 billion, an increase of 8.18%.
Analyst Forecasts
According to 3 analysts, the average rating for NVO stock is "Hold." The 12-month stock price forecast is 79.96, which is an increase of 14.87% from the latest price.